ロード中...
Strategies for Recognizing and Managing Immune‐Mediated Adverse Events in the Treatment of Hodgkin Lymphoma with Checkpoint Inhibitors
The programmed death‐1 (PD‐1) receptor checkpoint inhibitors nivolumab and pembrolizumab represent an important therapeutic advance in the treatment of relapsed or refractory classical Hodgkin lymphoma (cHL). Clinical trials have shown substantial therapeutic activity and an acceptable safety profil...
保存先:
| 出版年: | Oncologist |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
AlphaMed Press
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6324643/ https://ncbi.nlm.nih.gov/pubmed/30082490 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0045 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|